Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 3/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6794465 | 0.87 | PDPK1 (0.37) | PDPK1CDK2KDM4ETSHRHSD17B10 | |
| SCHEMBL6792846 | 0.86 | PDPK1 (0.31) | PDPK1CDK2 | |
| SCHEMBL6792586 | 0.84 | PLK1 (0.31) | PDPK1CDK2 | |
| SCHEMBL4270469 | 0.81 | PDPK1 (0.38) | PDPK1CDK2 | |
| SCHEMBL4444669 | 0.77 | CDK2 (0.38) | PDPK1CDK2 | |
| SCHEMBL6794205 | 0.77 | CDK2 (0.38) | PDPK1CDK2 | |
| SCHEMBL6794533 | 0.77 | CDK2 (0.37) | PDPK1CDK2 | |
| SCHEMBL4263045 | 0.77 | CDK2 (0.37) | PDPK1CDK2TSHR | |
| SCHEMBL4260282 | 0.76 | PLK1 (0.35) | PDPK1CDK2 | |
| SCHEMBL6794904 | 0.76 | PLK1 (0.35) | PDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PDPK1 87/4885CDK2 29/4885KDM4E 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.